PLYMOUTH MEETING, PA — INOVIO (NASDAQ: INO) has unveiled encouraging new immunology data for its lead product candidate, INO-3107, which is designed to treat recurrent respiratory papillomatosis (RRP), a condition caused by HPV-6 and HPV-11. Presented at the 36th International Papillomavirus Conference in Edinburgh, the findings build on previous Phase 1/2 trial results, highlighting the drug’s ability to reduce the need for surgical interventions in RRP patients.
The new data demonstrate that INO-3107 induces the expansion of clonal T cells that migrate from the bloodstream to papilloma and airway tissues. These T cells were predominantly observed in patients who showed a complete or partial response to the treatment. Dr. Matthew Morrow, Vice President of Translational Sciences at INOVIO, stated, “These new immunology data are consistent with the clinical effect observed in our Phase 1/2 trial of elimination or reduction in the incidence of papilloma in the airway of RRP patients.”
In the trial, 81.3% of patients experienced fewer surgeries after receiving INO-3107, with 28.1% requiring no surgical intervention during or after treatment. This is significant given that surgical removal is the current standard of care, often leading to repeated procedures due to regrowth.
Dr. Bettie M. Steinberg, Interim Dean at Northwell Health, remarked on the findings: “This is very encouraging data. Not only did most patients improve clinically with INO 3107 treatment, but the induction of a systemic inflammatory T-cell response and new T-cell clones that travel to the papilloma tissue to contribute to a cytotoxic response shows that it is possible to effectively address the immune dysregulation against HPV that is a hallmark of RRP.”
The treatment’s impact on T cell responses, including the expansion of new clonal populations and induction of an inflammatory response, suggests potential long-term benefits. INOVIO plans to leverage these positive outcomes to advance regulatory processes. The FDA has already granted INO-3107 Orphan Drug and Breakthrough Therapy designations, allowing for expedited review.
INOVIO’s ongoing commitment to developing DNA medicines like INO-3107 aims to provide effective therapeutic options for diseases with significant unmet needs, positioning the company at the forefront of medical innovation.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.